...
首页> 外文期刊>Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer >Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy
【24h】

Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy

机译:淋巴结血症状和乳腺癌幸存者的肢体测量变化,用新辅助化疗和腋窝解剖治疗:美国外科医学院肿瘤学院的结果(ACOSOG)Z1071(联盟)蜕皮

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PurposeLymphedema is a potential complication of breast cancer treatment. This longitudinal substudy aimed to prospectively assess arm measurements and symptoms following neoadjuvant chemotherapy and axillary dissection in the ACOSOG/Alliance Z1071 trial to characterize the optimal approach to define lymphedema.MethodsZ1071 enrolled patients with cT0-4, N1-2, M0 disease treated with neoadjuvant chemotherapy. All patients underwent axillary dissection. Bilateral limb volumes, circumferences, and related symptoms were assessed pre-surgery, 1-2weeks post-surgery, and semiannually for 36months. Lymphedema definitions included volume increase 10% or limb circumference increase 2cm. Symptoms were assessed by the Lymphedema Breast Cancer Questionnaire.ResultsIn 488 evaluable patients, lymphedema incidence at 3years by 10%-volume-increase was 60.3% (95% CI 55.0-66.2%) and by 2cm-circumference increase was 75.4% (95% CI 70.8-80.2%). Symptoms of arm swelling and heaviness decreased from post-surgery for the first 18months and then were relatively stable. The 3-year cumulative incidence of arm swelling and heaviness was 26.0% (95% CI 21.7-31.1%) and 30.9% (95% CI 26.3-36.3%), respectively. There was limited agreement between the two measurements (kappa 0.27) and between symptoms and measurements (kappa coefficients ranging from 0.05-0.09).ConclusionsLymphedema incidence by limb volume and circumference gradually increased over 36months post-surgery, whereas lymphedema symptoms were much lower. These findings underscore the importance of prospective surveillance and evaluation of both limb measurements and symptom assessment. Lymphedema incidence rates varied by definition. We recommend that 10% volume change criterion be used for lymphedema evaluation for referral for specialist care.Trial registrationNCT00881361
机译:PurpoSelyMpheDema是乳腺癌治疗的潜在并发症。这种纵向归档旨在在痤疮/联盟Z1071试验中进行Neoadjuvant化疗和腋窝扫描后的腋下测量和症状,以表征定义淋巴管的最佳方法。用Neoadjuvant治疗的CT0-4,N1-2,M0疾病患者患有Nethedsz1071患者化疗。所有患者均接受腋窝剖检。双侧肢体,周长和相关症状评估前术前手术,手术后1-2周,以及36个月的半年。淋巴米可定义包括体积增加10%或肢周长增加2cm。症状通过淋巴牛乳腺癌调查问卷评估488评价患者,3年的淋巴水肿发病率为10%-volumum-adm,60.3%(95%CI 55.0-66.2%)和2cm圆周增长为75.4%(95%) CI 70.8-80.2%)。手臂肿胀和沉重的症状从前手术后减少了前18个月,然后相对稳定。 3年累积的臂膨胀和沉重发病率为26.0%(95%CI 21.7-31.1%)和30.9%(95%CI 26.3-36.3%)。两项测量(Kappa 0.27)和症状和测量之间存在有限的一致性(κ0.09的κ系数范围)。肢体骨骼和围绕手术后36个月逐渐增加,淋巴结症状均低于36个月的症状。这些发现强调了前瞻性监测和评估肢体测量和症状评估的重要性。淋巴水肿发病率因定义而变化。我们建议使用10%的体积变更标准,用于专业护理的推荐淋巴模评估.TIAL ENGINEDIONNCT00881361

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号